HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: R300004-MCP200v1 2/6/388    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Admon, A. Articles by Ziv, T. Search for Related Content PubMed PubMed Citation Articles by Admon, A. Articles by Ziv, T. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 2:388-398, 2003.
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Review

Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides^*

Arie Admon, Eilon Barnea and Tamar Ziv

From the Department of Biology, Technion, Haifa 32000, Israel

The major histocompatibility complex (MHC) peptide repertoire of cancer cells serves both as a source for new tumor antigens for development of cancer immunotherapy and as a rich information resource about the protein content of the cancer cells (their proteome). Thousands of different MHC peptides are normally displayed by each cell, where most of them are derived from different proteins and thus represent most of the cellular proteome. However, in contrast to standard proteomics, which surveys the cellular protein contents, analyses of the MHC peptide repertoire correspond more to the rapidly degrading proteins in the cells (i.e. the transient proteome). MHC peptides can be efficiently purified by affinity chromatography from membranal MHC molecules, or preferably following transfection of vectors for expression of recombinant soluble MHC molecules. The purified peptides are resolved and analyzed by capillary high-pressure liquid chromatography-electrospray ionization-tandem mass spectrometry, and the data are deciphered with new software tools enabling the creation of large databanks of MHC peptides displayed by different cell types and by different MHC haplotypes. These lists of identified MHC peptides can now be used for searching new tumor antigens, and for identification of proteins whose rapid degradation is significant to cancer progression and metastasis. These lists can also be used for identification of new proteins of yet unknown function that are not detected by standard proteomics approaches. This review focuses on the presentation, identification and analysis of MHC peptides significant for cancer immunotherapy. It is also concerned with the aspects of human proteomics observed through large-scale analyses of MHC peptides.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M.-H. Fortier, E. Caron, M.-P. Hardy, G. Voisin, S. Lemieux, C. Perreault, and P. Thibault The MHC class I peptide repertoire is molded by the transcriptome J. Exp. Med., March 17, 2008; 205(3): 595 - 610. [Abstract] [Full Text] [PDF]

				A. O. Weinzierl, C. Lemmel, O. Schoor, M. Muller, T. Kruger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, et al. Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface Mol. Cell. Proteomics, January 1, 2007; 6(1): 102 - 113. [Abstract] [Full Text] [PDF]

				A. L. Zarling, J. M. Polefrone, A. M. Evans, L. M. Mikesh, J. Shabanowitz, S. T. Lewis, V. H. Engelhard, and D. F. Hunt From the Cover: Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy PNAS, October 3, 2006; 103(40): 14889 - 14894. [Abstract] [Full Text] [PDF]

				E. Milner, E. Barnea, I. Beer, and A. Admon The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells Mol. Cell. Proteomics, February 1, 2006; 5(2): 357 - 365. [Abstract] [Full Text] [PDF]

				A. W. Purcell and J. J. Gorman Immunoproteomics: Mass Spectrometry-based Methods to Study the Targets of the Immune Response Mol. Cell. Proteomics, March 1, 2004; 3(3): 193 - 208. [Abstract] [Full Text] [PDF]